By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Gen-Probe and DiagnoCure said today that Gen-Probe has received a regulatory medical device license from Health Canada, the Canadian government's department responsible for national public health, for a molecular urine test that determines the need for repeat biopsies for prostate cancer.

Gen-Probe exclusively licensed the worldwide rights to the PCA3 gene, on which its Progensa PCA3 assay is based, from its commercial partner DiagnoCure in 2003.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

An Australian study of personalized medicine has run into problems as it recruits patients.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.